Neuraltus Pharmaceuticals, Inc. is a privately-held biopharmaceutical company dedicated to developing and commercializing therapeutics that address critical unmet needs in the treatment of neurodegenerative diseases.
Our lead product, NP001, is in clinical development for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease in the U.S. and motor neurone disease (MND) in Europe. Neuraltus has completed enrollment of a second Phase 2 clinical study of NP001 to confirm the previous Phase 2 findings in ALS patients with elevated levels of baseline inflammation. Neuraltus recognizes that ALS is a devastating condition with only two approved therapies, and we are focused on developing and bringing NP001 to market as quickly as possible. We strive to be a committed partner to the ALS community and work closely with patient advocacy organizations to better understand the needs of people affected by this disease.